• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型半合成大环内酯类药物YM133的体外活性

In vitro activity of YM133, a new semisynthesized macrolide.

作者信息

Terasawa T, Watanabe M, Okubo T, Mitsuhashi S

机构信息

Episome Institute, Seta-gun, Japan.

出版信息

Antimicrob Agents Chemother. 1991 Jul;35(7):1370-5. doi: 10.1128/AAC.35.7.1370.

DOI:10.1128/AAC.35.7.1370
PMID:1929295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC245174/
Abstract

YM133, the 4"-O-(4-methoxyphenyl)acetyltylosin, is a new macrolide. The in vitro activity of YM133 was compared with those of erythromycin, josamycin, and rokitamycin by an agar dilution method. YM133 inhibited 90% of the tested isolates of Streptococcus pneumoniae, Legionella spp., and anaerobic bacteria at less than or equal to 1.56 micrograms/ml. The drug inhibited 90% of erythromycin-resistant staphylococci and Streptococcus pyogenes at less than or equal to 50 micrograms/ml. YM133 showed activity against erythromycin-, josamycin-, and rokitamycin-resistant (MIC greater than or equal to 100 micrograms/ml) strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp. Enterococci were less susceptible to other YM133-like macrolides. Unlike other macrolides, YM133 showed killing activity, and the MBC/MIC ratios of YM133 for several strains were 1:32, whereas those of erythromycin were 4:1,024. In a time-kill curve study, the reduction of viable cells started within 2 h after the addition of YM133.

摘要

YM133,即4”-O-(4-甲氧基苯基)乙酰泰乐菌素,是一种新型大环内酯类抗生素。采用琼脂稀释法比较了YM133与红霉素、交沙霉素和罗他霉素的体外活性。YM133对90%的肺炎链球菌、军团菌属和厌氧菌测试菌株的抑制浓度小于或等于1.56微克/毫升。该药物对90%的耐红霉素葡萄球菌和化脓性链球菌的抑制浓度小于或等于50微克/毫升。YM133对葡萄球菌、链球菌、拟杆菌属和梭菌属中耐红霉素、交沙霉素和罗他霉素(最低抑菌浓度大于或等于100微克/毫升)的菌株具有活性。肠球菌对其他类似YM133的大环内酯类抗生素不太敏感。与其他大环内酯类抗生素不同,YM133具有杀菌活性,YM133对几种菌株的最低杀菌浓度与最低抑菌浓度之比为1:32,而红霉素为4:1024。在时间-杀菌曲线研究中,加入YM133后2小时内活菌数开始减少。

相似文献

1
In vitro activity of YM133, a new semisynthesized macrolide.新型半合成大环内酯类药物YM133的体外活性
Antimicrob Agents Chemother. 1991 Jul;35(7):1370-5. doi: 10.1128/AAC.35.7.1370.
2
Antibacterial activity of rokitamycin compared with that of other macrolides.与其他大环内酯类药物相比,罗他霉素的抗菌活性
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):331-5. doi: 10.1016/0732-8893(91)90024-a.
3
Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.采用Epsilometer试验评估化脓性链球菌红霉素耐药菌株对罗他霉素(一种16元大环内酯类抗生素)的药敏程度。
Drugs Exp Clin Res. 2004;30(1):17-26.
4
In vitro activity of MC-352, a new 16-membered macrolide.新型16元大环内酯类化合物MC-352的体外活性
Antimicrob Agents Chemother. 1992 Aug;36(8):1699-702. doi: 10.1128/AAC.36.8.1699.
5
[In vitro antibacterial activity of a new macrolide: miokamycin. Comparison with erythromycin and josamycin].一种新型大环内酯类抗生素:米卡霉素的体外抗菌活性。与红霉素和交沙霉素的比较
Pathol Biol (Paris). 1988 May;36(5):370-6.
6
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.16元环大环内酯类药物及泰利霉素对不同基因型的红霉素敏感及耐药化脓性链球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
7
High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.红霉素耐药、克林霉素/米诺卡霉素敏感(M表型)化脓性链球菌的高流行率:1998年西班牙多中心研究结果。西班牙初级卫生保健环境感染研究小组
J Antimicrob Chemother. 2000 May;45(5):605-9. doi: 10.1093/jac/45.5.605.
8
The post-antibiotic effects of rokitamycin (a 16-membered ring macrolide) on susceptible and erythromycin-resistant strains of Streptococcus pyogenes.罗他霉素(一种16元环大环内酯类抗生素)对化脓性链球菌敏感菌株及红霉素耐药菌株的抗生素后效应。
Int J Antimicrob Agents. 2004 Sep;24(3):254-60. doi: 10.1016/j.ijantimicag.2004.02.031.
9
[Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].[大环内酯类抗生素对近期临床分离株的抗菌活性及耐药机制分析]
Jpn J Antibiot. 2003 Jun;56(3):163-70.
10
[In vitro antibacterial activity of rokitamycin, a new macrolide antibiotic. Results of a multicenter study].[新型大环内酯类抗生素罗他霉素的体外抗菌活性。一项多中心研究的结果]
Pathol Biol (Paris). 1990 May;38(5):407-12.

引用本文的文献

1
Clostridium difficile drug pipeline: challenges in discovery and development of new agents.艰难梭菌药物研发进程:新型药物发现与开发面临的挑战
J Med Chem. 2015 Jul 9;58(13):5164-85. doi: 10.1021/jm5016846. Epub 2015 Mar 30.

本文引用的文献

1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
Studies of tylosin derivatives effective against macrolide-resistant strains: synthesis and structure-activity relationships.对耐大环内酯类菌株有效的泰乐菌素衍生物的研究:合成与构效关系
J Antibiot (Tokyo). 1982 Jun;35(6):661-72. doi: 10.7164/antibiotics.35.661.
3
Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors.金黄色葡萄球菌对苯唑西林最低杀菌浓度的测定:技术因素的影响及意义
Antimicrob Agents Chemother. 1983 Jan;23(1):142-50. doi: 10.1128/AAC.23.1.142.
4
4''-O-(4-methoxyphenyl)-acetyltylosin, a new macrolide derivative of therapeutic importance.4''-O-(4-甲氧基苯基)-乙酰泰乐菌素,一种具有治疗重要性的新型大环内酯衍生物。
J Antibiot (Tokyo). 1987 Sep;40(9):1358-60. doi: 10.7164/antibiotics.40.1358.
5
In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.新型口服头孢菌素ME1207的体外和体内抗菌活性
Antimicrob Agents Chemother. 1988 Sep;32(9):1421-6. doi: 10.1128/AAC.32.9.1421.
6
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.新型14元、15元及16元大环内酯类药物的体外活性比较
Antimicrob Agents Chemother. 1988 Nov;32(11):1710-9. doi: 10.1128/AAC.32.11.1710.
7
Synthesis and structure-activity studies of new 4''-O-acyltylosin derivatives of therapeutic interest.具有治疗意义的新型4''-O-酰基泰乐菌素衍生物的合成及构效关系研究
J Antibiot (Tokyo). 1988 Nov;41(11):1617-28. doi: 10.7164/antibiotics.41.1617.
8
Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.A-56268与红霉素及其他口服制剂针对需氧菌和厌氧菌的活性比较。
Antimicrob Agents Chemother. 1987 Mar;31(3):463-6. doi: 10.1128/AAC.31.3.463.
9
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.新型大环内酯类药物A-56268(TE-031)的体外和体内评估
Antimicrob Agents Chemother. 1986 Dec;30(6):865-73. doi: 10.1128/AAC.30.6.865.
10
Application of dibutyltin oxide method to regioselective acylation and alkylation of tylosin at C-4''.二丁基氧化锡法在泰乐菌素C-4''位区域选择性酰化和烷基化中的应用
Chem Pharm Bull (Tokyo). 1989 Apr;37(4):861-5. doi: 10.1248/cpb.37.861.